Questionnaire in Screening Older Patients With Cancer
|ClinicalTrials.gov Identifier: NCT00963911|
Recruitment Status : Completed
First Posted : August 24, 2009
Last Update Posted : May 13, 2011
RATIONALE: A screening questionnaire may help doctors plan better treatment for older patients with cancer.
PURPOSE: This clinical trial is studying a questionnaire in screening older patients with cancer.
|Condition or disease||Intervention/treatment|
|Breast Cancer Colorectal Cancer Head and Neck Cancer Lung Cancer Lymphoma Prostate Cancer||Other: medical chart review Other: screening questionnaire administration Procedure: comparison of screening methods Procedure: quality-of-life assessment|
- Validate a new screening tool (G8).
- Validate the French version of the screening tool "Vulnerable Elders Survey (VES-13)".
- Evaluate the merits of the screening tools (G8 and VES-13).
- Assess the screening tool in specific populations.
- Assess the number and type of interventions proposed after thorough geriatric assessment.
- Compare the two new tools (G8 vs VES-13).
OUTLINE: This is a multicenter study.
During the first consultation, patients have an initial clinical evaluation questionnaire comprising the G8. They also complete the self-questionnaire VES-13. Within 30 days, patients have a thorough geriatric assessment, including quality of life and physical function, by a physician without access to the G8 or VES-13 questionnaires. A blood specimen is also collected.
Information on health status and quality of life is collected from medical records or from the doctor after 1 and 5 years.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||1650 participants|
|Masking:||None (Open Label)|
|Official Title:||Validation of a Screening Tool in Geriatric Oncology|
|Study Start Date :||June 2008|
|Primary Completion Date :||May 2011|
- Validation of G8 screening tool
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00963911
|Bordeaux, France, 33076|
|Principal Investigator:||Pierre Soubeyran, MD, PhD||Institut Bergonié|